KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Non-Current Assets (2016 - 2025)

Historic Non-Current Assets for NovoCure (NVCR) over the last 12 years, with Q3 2025 value amounting to $161.3 million.

  • NovoCure's Non-Current Assets rose 2732.21% to $161.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $161.3 million, marking a year-over-year increase of 2732.21%. This contributed to the annual value of $134.2 million for FY2024, which is 2012.98% up from last year.
  • As of Q3 2025, NovoCure's Non-Current Assets stood at $161.3 million, which was up 2732.21% from $162.6 million recorded in Q2 2025.
  • NovoCure's Non-Current Assets' 5-year high stood at $162.6 million during Q2 2025, with a 5-year trough of $51.4 million in Q3 2021.
  • Its 5-year average for Non-Current Assets is $99.1 million, with a median of $93.5 million in 2023.
  • In the last 5 years, NovoCure's Non-Current Assets surged by 816.37% in 2021 and then skyrocketed by 3964.27% in 2022.
  • Quarter analysis of 5 years shows NovoCure's Non-Current Assets stood at $66.0 million in 2021, then increased by 21.45% to $80.1 million in 2022, then surged by 39.44% to $111.7 million in 2023, then increased by 20.13% to $134.2 million in 2024, then rose by 20.22% to $161.3 million in 2025.
  • Its Non-Current Assets was $161.3 million in Q3 2025, compared to $162.6 million in Q2 2025 and $159.5 million in Q1 2025.